Enhancing T-cell function for leukemia treatment
BCL11B activation as an approach for enhancing the efficacy of immunotherapy
This study is looking at how a protein called BCL11B can help improve the recovery of T-cells after stem cell transplants and make CAR T-cell therapies work better for people with leukemia, aiming to help patients have stronger immune responses and reduce the chances of infections or cancer coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11012274 on NIH RePORTER |
What this research studies
This research investigates the role of the BCL11B transcription factor in improving T-cell recovery after stem cell transplants and boosting the effectiveness of CAR T-cell therapies for leukemia. By focusing on the overexpression of BCL11B, the study aims to address challenges such as slow T-cell generation and T-cell exhaustion, which can lead to infections and cancer relapse. The approach involves understanding how BCL11B can enhance T-cell differentiation and function, potentially leading to better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with acute B-lymphocytic leukemia who are undergoing or considering allogeneic hematopoietic stem cell transplantation or CAR T-cell therapy.
Not a fit: Patients with other types of leukemia or those who are not eligible for stem cell transplantation or CAR T-cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for leukemia, improving survival rates and reducing complications for patients undergoing stem cell transplants or CAR T-cell therapy.
How similar studies have performed: Other research has shown promise in enhancing T-cell function through genetic modifications, suggesting that this approach could yield significant advancements in leukemia treatment.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Parekh, Chintan — Beckman Research Institute/city of Hope
- Study coordinator: Parekh, Chintan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.